Caspin Resources Limited (ASX:CPN) Reports Maiden RC Drilling Results
Caspin Resources (ASX:CPN) reveals maiden RC drilling results at Bygoo North, showing a 100m tin intersection.
Tag: Industry-Specific News
Far East Gold Ltd (ASX:FEG) Announces Idenburg Drill Program
Far East Gold Ltd (ASX:FEG) launches a 3,670m drill program to expand its Idenburg gold resources in Papua.
Chariot Corporation Ltd (ASX:CC9) Raises Up to A$2 Million via Convertible Notes
Chariot Corporation Ltd (ASX:CC9) raises up to A$2 million through convertible notes to advance exploration projects and strengthen its balance sheet.
Silver Mines Limited (ASX:SVL) Commences Diamond Drilling at Bowdens Project
Silver Mines Limited (ASX:SVL) commences diamond drilling at Bowdens Silver Project to potentially expand Ore Reserve and extend mine life.
Everest Metals Corporation Ltd (ASX:EMC) Commences 6,000m Aircore Drilling at Revere Gold Project
Everest Metals Corporation Ltd (ASX:EMC) has initiated a 6,000m Aircore drilling campaign at its Revere Gold Project, aiming to advance its JORC Mineral Resource Estimate by late Q2 2025.
James Bay Minerals (ASX:JBY) Commences Drilling at Independence Project
James Bay Minerals (ASX:JBY) begins a 4,000m drill program at Independence Project’s Rebel Trend, targeting significant gold resource growth.
Desert Metals Limited (ASX:DM1) Commences Drilling Programs and Secures Placement
Desert Metals (ASX:DM1) initiates comprehensive drilling programs in Côte d’Ivoire and secures AUD 3.25m funding through placement.
Resolution Minerals (ASX:RML) Acquires High-Grade Antimony-Gold Portfolio
Resolution Minerals (ASX:RML) acquires high-grade antimony and gold projects in NSW and QLD, enhancing its strategic mining portfolio.
BMG Resources (ASX:BMG) Accelerates Gold Exploration in Western Australia
BMG Resources (ASX:BMG) accelerates gold exploration at Bullabulling and Invincible Projects, leveraging high-grade discoveries and strategic acquisitions.
Prescient Therapeutics (ASX:PTX) Initiates Phase 2a PTX-100 Clinical Study
Prescient Therapeutics (ASX:PTX) initiates Phase 2a clinical study for PTX-100, marking a significant milestone in treating Cutaneous T-Cell Lymphoma.